Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Related video Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) or CIS plus papillary disease […]

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Related video AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., (Merck: known as MSD outside the US and Canada) today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA® (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or […]

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Related video Radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease, according to results from a pre-planned analysis of a large comparison study reported at ESMO 2018. “Standard treatment for men newly diagnosed […]

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Related video Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) who have achieved disease control with induction treatment. […]

HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study

Related video A new study reveals that Hispanic HIV-infected adults in the United States are at a higher risk of developing cancers caused by the human papillomavirus (HPV) than Hispanics from the general population. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings highlight the need for continued efforts […]

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Related video Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich. Prof. Peter Schmid, first author, said the results “will change the way triple-negative breast cancer is treated”. “Atezolizumab in combination with nab-paclitaxel is the first […]

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Related video Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in […]

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Related video Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich. “Our results suggest promise for the use of biomarker-guided neoadjuvant […]

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Related video Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this […]